专利检索 ap:("Sirnaomics, Inc." OR "Jia Zhou" OR "Qingfeng Li") AND inv:"John Xu" 第 1 页

1.

发明授权
Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis 有权

公开(公告)号：US11697813B2

公开(公告)日：2023-07-11

申请号：US16343309

申请日：2017-10-30

申请人： Sirnaomics, Inc. , Jia Zhou , Qingfeng Li

发明人： John Xu , Patrick Y. Lu , Jia Zhou , Qingfeng Li , Vera Simonenko

IPC分类号： C07H21/02 , C07H21/04 , C12N15/113 , A61K31/713 , A61K47/34

CPC分类号： C12N15/1136 , A61K31/713 , A61K47/34 , C12N15/1137 , C12N2310/14 , C12N2320/30

摘要： The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

2.

发明申请
sirna/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral Infection 审中-公开

公开(公告)号：US20190030187A1

公开(公告)日：2019-01-31

申请号：US15758312

申请日：2016-09-07

申请人： Sirnaomics, Inc.

发明人： Patrick Y. Lu , Vera Simonenko , Yibin Cai , John Xu , David Evans

IPC分类号： A61K48/00 , A61P31/14 , A61K47/54 , A61K47/28 , C12N15/113

摘要： The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

3.

发明授权
Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV) 有权

公开(公告)号：US12006500B2

公开(公告)日：2024-06-11

申请号：US17157920

申请日：2021-01-25

申请人： Sirnaomics, Inc.

发明人： Danny Tang , Xueping Chen , Patrick Y. Lu , Vera Simonenko , David Evans , John Xu , Deling Wang , Alan Lu

IPC分类号： C12N15/113 , A61K9/51 , A61K31/713 , A61K47/28 , A61K47/69 , A61P31/14

CPC分类号： C12N15/113 , A61K9/513 , A61K31/713 , A61K47/28 , A61K47/6931 , A61P31/14

摘要： Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.

4.

发明授权
Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection 有权

公开(公告)号：US11058779B2

公开(公告)日：2021-07-13

申请号：US15758312

申请日：2016-09-07

申请人： Sirnaomics, Inc.

发明人： Patrick Y. Lu , Vera Simonenko , Yibin Cai , John Xu , David Evans

IPC分类号： A61K48/00 , C12N15/11 , C07H21/02 , C07H21/04 , A61K9/51 , A61K9/127 , A61K47/54 , A61P31/14 , A61K47/28 , C12N15/113 , C12N15/88 , B82Y5/00

摘要： The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.